Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’'s study on “"Hematologists’' Approach to Discussing Older Patients’ Values in the Context of Allogeneic Hematopoietic Cell Transplantation”" explored the methodologies hematologists use to engage older patients in treatment decisions, highlighting key findings related to patient values and the importance of incorporating these factors into transplant decision-making for improved patient-centered care.
Video content above is prompted by the following:
Liso-Cel Improves Outcomes in R/R CLL/SLL Following 2 or More Lines of Therapy
June 26th 2025Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.
Read More
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More